SEC Form 4 · accession 0001209191-17-049546
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil F. McFarlane
Officer — Chief Operating Officer
Period of report
Aug 16, 2017
Accepted (ET)
Aug 17, 2017 · 8:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 16, 2017 | S | 1,378 | $22.50 | D | 13,622 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares were sold to cover the tax obligation that occurred upon the vesting of an RSU.